SCHEMBL30674488

SCHEMBL30674488

C#CNC(=O)CCCC#Cc1cnc(S(C)(=O)=O)nc1

nearest known ligand 0.32

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ NPC1 O15118 1/20 0.31
▸ TP53 P04637 1/20 0.31
▸ XBP1 P17861 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HTT P42858 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ TLR9 Q9NR96 1/20 0.31
▸ THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22551273 0.87 CYP1A2 (0.32) ALDH1A1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL21137867 0.86 CYP1A2 (0.34) ALDH1A1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL22618750 0.84 FAAH (0.36) ALDH1A1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL29263596 0.83 ALDH1A1 (0.35) ALDH1A1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL22561348 0.83 ALDH1A1 (0.32) ALDH1A1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL25045553 0.82 FFAR1 (0.32) ALDH1A1MAPTNPC1TP53XBP1
SCHEMBL22551277 0.82 FFAR1 (0.40) ALDH1A1MAPT
SCHEMBL22618814 0.82 FFAR1 (0.32) ALDH1A1MAPTNPC1TP53XBP1
SCHEMBL22618760 0.81 ITGB1 (0.41) ALDH1A1MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL30107915 0.81 ACACB (0.34) ALDH1A1MAPTCYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250281631-A1 ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2025-09-11 — — US disclosed
EP-4514396-A1 ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-03-05 — — EP disclosed
CN-119212732-A Antibody drug conjugate, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-12-27 — — CN disclosed
WO-2023208216-A9 ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2024-08-29 — — WO disclosed
WO-2023208216-A1 ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281631-A1 ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF TOP1, TOP2A, TOP2B ALDH1A1 3902/4885MAPT 3156/4885CYP1A2 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback